Effects of Early, Late and Long-term Non-Selective Beta-Blockade on Left Ventricular Remodeling, Function and Survival in Chronic Organic Mitral Regurgitation

Pu et al: Beta-blockade in Chronic Mitral Regurgitation

Min Pu, MD, PhD; Zhaohui Gao, MD; Daniel K. Pu, MD; William R. Davidson Jr., MD

1Wake Forest University School of Medicine, 2Penn State University College of Medicine, 3University of Cincinnati College of Medicine

Correspondence to:
Min Pu, MD, PhD
Section of Cardiology
Wake Forest Baptist Health, School of Medicine
Medical Center Boulevard
Winston-Salem, NC 27157
Tel: 336-716-0817
Fax: 336-716-4995
Email: mpu@wfubmc.edu

DOI: 10.1161/CIRCHEARTFAILURE.112.000196

Journal Subject Code: 19
Abstract

Background—Mitral regurgitation (MR) produces sympathetic nervous system activation which is detrimental in other causes of heart failure. However, whether β-blockade is beneficial in MR has not been determined.

Methods and Results—Eighty-seven rats with significant organic MR were randomized to the β-blockade group (n=43) or the control group (n=44). Carvedilol was started in week 2 post MR induction and given for 23-35 weeks in the β-blockade group. Echocardiography was performed at baseline and at weeks 2, 6, 12, 24, 30 and 36 after MR induction. After 23 weeks of β-blockade, heart rates were significantly reduced by carvedilol (308 ± 25 vs. 351 ± 31 beats/min, p<0.001). Left ventricular (LV) end-diastolic (2.2 ± 0.7 ml vs. 1.59 ± 0.6 ml, p<0.001), end-systolic volumes (0.72 ± 0.42 ml vs. 0.40 ± 0.19 ml, p<0.001) and mass index (2.40 ± 0.55 vs. 2.06 ± 0.62 g/kg, p<0.001) were significantly higher and LV fraction shortening (33 ± 7% vs. 38 ± 7%, p<0.001) and ejection fraction (69 ± 11% vs. 75 ± 7%, p<0.001) significantly lower in the β-blockade group than the control group. Systolic blood pressure was lower in the β-blockade group than the control group (114 ± 10 mmHg vs. 93 ± 12 mmHg, p<0.005). Survival probability was significantly lower in the early β-blockade group than the control group (88% vs. 96%, p=0.03).

Conclusions—Early and long-term non-selective β-blockade was associated with adverse LV remodeling, systolic dysfunction and a reduction in survival in the experimental rat model of organic MR.

Key Words: mitral regurgitation; β-blocker, left ventricular remodeling; left ventricular function.
There are more than 5,000,000 patients suffering from moderate to severe valvular regurgitation in the United States. The Framingham Study noted that the prevalence of mitral regurgitation (MR) increases 1.3 fold with each decade of life.\(^1\) It is anticipated that the prevalence of MR will increase even further due to the rapidly growing aged population in the United States and worldwide.

Early surgical intervention in chronic organic MR has been advocated in recent years, especially when mitral valve repair appears feasible. However, the majority of patients with chronic MR do not undergo surgical intervention. For example, there are 500,000 hospital discharges with the diagnosis of mitral-valve disease each year in the United States, but only about 18,000 patients (3.6\%) undergo mitral-valve surgery annually.\(^2\) There is an on-going debate on optimal management strategy for asymptomatic patients with chronic MR and normal LV function, particularly when mitral valve repair is not feasible or significant co-morbidities are present.\(^3\) Therefore, clinicians have long been interested in finding non-surgical therapies for chronic MR. Traditional drugs for the treatment of congestive heart failure including vasodilators \(^4,5\) and angiotensin-converting enzyme inhibitors have been tested.\(^6\) Although these medications may have acute favorable hemodynamic effects in MR, they have not shown promising results in limited long-term studies.\(^6\) A small clinical observational study showed that carvedilol improved LV remodeling and reduced MR in patients with congestive heart failure caused by non-valvular heart disease (ischemic heart disease or non-ischemic cardiomyopathy).\(^7\) A retrospective study showed \(\beta\)1-blockade could prolong survival in mitral regurgitation, although this study was significantly limited by many confounding factors.\(^8\) Since \(\beta\)-blocker therapy is beneficial for heart failure not due to MR, it is reasonable to hypothesize that \(\beta\)-blockade could have beneficial effects in congestive heart failure caused by chronic organic MR. In particular, the benefits might
be more pronounced if β-blockade were started early, prior to the development of irreversible LV dysfunction. Animal studies have shown that β-blockade could improve LV systolic function in chronic MR. Recent clinical studies have also shown that β1-blockade may improve LV systolic function in chronic organic MR, but a beneficial effect on LV remodeling is uncertain. There have been no studies yet demonstrating that β-blockade improves LV remodeling in chronic organic MR. Furthermore, a dissociation between adverse LV remodeling and improvement in cardiac myocyte contractility in experimental MR treated with β-blockers has been reported. This dissociation creates a possible pathophysiological contradiction as adverse LV remodeling is often associated with LV dysfunction and poor long-term outcome in all forms of congestive heart failure. Therefore, it is important to determine whether beneficial effects of β-blockade could be demonstrated if chronic organic MR were treated in the early stages prior to the development of LV dysfunction and if treatment is long-term. It is also imperative to determine whether LV remodeling associated with β-blocker therapy could ultimately have a negative impact on LV function in chronic organic MR or if the early improvement in LV function and myocardial contractility observed in prior studies could lead to improvement in LV remodeling if treatment were initiated early and long-term. In order to clarify this important issue, we carried out a prospective study to determine the effects of early, late and long-term β-blockade on LV remodeling, systolic function and survival in experimental chronic MR. The study design had the following unique characteristics: 1) the study used a unique rat model of chronic MR developed in our laboratory, allowing us to use a large numbers of animals to test the hypothesis; 2) carvedilol (a nonselective β-adrenergic blocking agent with α1-blocking activity) was administered early before the development of LV systolic dysfunction; 3) a long-term treatment strategy was applied.
Methods

Rat Model of MR

The study protocol was approved by the Institution’s Animal Care and Use Committee of the Pennsylvania State University College of Medicine (assurance number A3045-01). The study was performed according to the guidelines of the American Society of Physiology. The study used Sprague-Dawley rats (180g-339). Mitral regurgitation was induced using techniques which were previously described.16 An intracardiac echocardiographic catheter (Acuson/Siemens Corporation, Mountain View, CA) was used to obtain transesophageal echocardiographic images to assess the severity of MR.17 MR was considered significant if a regurgitant jet area occupied more than 40% of left atrial area and/or a reversed pulmonary venous flow pattern was detected with a visible MR vena contracta.

Beta-Blockade

A total of 114 rats underwent MR induction surgery. Eighty-seven rats survived perioperatively (7 days post-surgery) with significant MR. Among them, 43 rats were randomized into the β-blockade group and 44 rats were randomized into the control group in the early stage of MR. Carvedilol (GlaxoSmithKline) was added to the rat chow (1200 parts per million in a Harlan Teklad Global Diet).18 In the early β-blockade group, β-blocker diet was initiated at 2nd week post MR induction. After echocardiography was performed at the 24-week mark of MR induction, surviving rats in the early control group (n=42) were re-randomized into late β-blockade group and late control group (no β-blockade). Rats in the early β-blockade group were re-randomized into long-term β-blockade group (continued carvedilol treatment) and β-blockade
withdrawn group (discontinued carvedilol). This helped evaluate whether rats absorbed carvedilol by observation of changes in blood pressure and heart rates after carvedilol was withdrawn. The study protocol is summarized in Figure 1.

**Echocardiography**

Two-dimensional, color Doppler, and pulsed-wave Doppler imaging were performed using a special probe for small animals (14 MHz, Acuson/Siemens Corporation, Mountain View, CA). Parasternal long- and short-axis two-dimensional views were recorded as previously described.\textsuperscript{19} M-mode images were obtained at the level of the chordae tendineae of the mitral valve in the short-axis view under the guidance of two-dimensional imaging. In order to assess the time course of LV remodeling, transthoracic echocardiography was performed at baseline prior to MR induction, and at weeks 2, 6, 12, 24, 30 and 36 post MR induction. All images were recorded digitally. Echocardiography parameters were measured blinded to the assignment of the \( \beta \)-blockade and non-\( \beta \)-blockade groups. Measurements were averaged for three cardiac cycles.

*Assessment of LV Remodeling:* LV end-diastolic dimension (LVEDD), LV end-systolic dimension (LVESD), interventricular septal (IVS) thickness and LV posterior wall thickness (PW) were measured from M-mode echocardiography as recommended by the American Society of Echocardiography.\textsuperscript{20} LVEDD/wall thickness ratio was calculated as \((\text{LVEDD}/2)/\text{LVPW}\) and LV mass was calculated as \textsuperscript{21}

\[
\text{LV mass} = 1.04 \times [(\text{LVEDD}+\text{PW}+\text{IVS})^3 - \text{LVEDD}^3] \times 0.8+0.14
\]
LV mass/weight index was calculated as LV mass divided by body weight (kilogram). LV end-diastolic volume (LVEDV) and LV end-systolic dimension (LVESD) were calculated as LVEDV = LVEDD$^3 \times \pi/3$ and LVESV= LVESD$^3 \times \pi/3$ respectively.22 LV volume/mass ratio was calculated as LV volume divided by LV mass.

Assessment of Systolic Function: LV fractional shortening (LVFS), LV ejection fraction (LVEF), LVESD and LVESV were measured for the assessment of LV systolic function. LVFS was calculated as LVFS = (LVEDD-LVESD)/LVEDD $\times$ 100%. LVEF was calculated as LVEF = (LVEDV-LVESV)/LVEDV $\times$ 100%.

Heart Rate and Blood Pressure Measurement
Heart rates were measured from electrocardiographic monitoring during the echocardiography study. Invasive blood pressure measurements were performed at weeks 36-56 (46 ±7 weeks) post MR induction in 13 rats in the late control group, 13 rats in the late $\beta$-blockade group, 15 rats in the $\beta$-blockade withdrawn group and 9 rats in the long-term $\beta$-blockade group. Briefly, the carotid artery was isolated and a Millar catheter was inserted into the carotid artery and advanced into the ascending aorta to record blood pressure. Blood pressure data was transferred to PowerLab (AD Instrument, Colorado, USA). Systolic and diastolic pressures were measured offline blinded to the assignment of the $\beta$-blockade and non-$\beta$-blockade groups.
Statistical Analysis

All data are expressed as mean ± SD. Measurements of LV volumes, mass and function were obtained at week 2 prior to the randomization and then at weeks 6, 12, and 24. Repeated measures analysis of covariance was used to test the overall main effect of the treatment on the follow-up measures using the baseline and week 2 as covariates. Group by time interaction was also tested to see if the effect was similar at each of the three follow-up times. Since there were some group by week interactions, post-hoc comparisons between the groups at the follow-up weeks were performed at the individual follow-up times. Kaplan-Meier curves were used to estimate the survival probabilities and the curves were compared using the log-rank test.

Results

Effect of Early β-Blockade on Heart Rate

Changes in heart rates in the early β-blockade and control group are illustrated in Table 1. There were no significant differences in heart rates between the MR control group and β-blockade group at baseline and week 2 post MR induction before carvedilol was started. However, there was a significant decrease in heart rates in the β-blockade group at weeks 6, 12 and 24. Heart rates were also significantly lower in the late β-blockade group than the late control group in weeks 30 (311± 35 vs. 334 ± 35 beats/min, p<0.001) and weeks 36 (307± 43 beat/min vs. 341 ± 29 beats/min, p<0.001). Heart rates increased from 302 ± 21 beats/min to 343 ± 34 beats/min at week 30 to 342 ± 30 beats/min at week 36 in the β-blockade withdrawn group, which were significantly higher than the long-term β-blockade group (309 ± 32 beats/min at week 30, p<0.001; 309 ± 30 beats/min at week 36, p<0.001).
Effects of β-Blockade on Blood Pressure

Table 2 shows the invasive blood pressure measurements. Systolic and diastolic blood pressures were significantly lower in the late and long-term β-blockade groups than the late control group and β-blockade withdrawn group. There was no statistical difference in systolic and diastolic blood pressures between the late control group and the β-blockade withdrawn group indicating that carvedilol lowers BP in rat models of chronic MR.

Effect of Early β-Blockade on LV Remodeling and Function

Table 3 shows effect of β-blockade on LV volume, mass and function. There were no significant differences in LV end-diastolic and end-systolic volumes between the β-blockade and control group at baseline (before MR induction) and at week 2 prior to the administration of carvedilol. Increases in LV volumes were noted in both groups at week 2 due to volume overload caused by MR. LV volumes and mass increased more significantly and rapidly in the β-blockade group (weeks 6, 12, 24). LVESV, LVEF and LVFS were used as indices of LV systolic function. There were no significant differences in LVFS and LVEF at baseline and at week 2 between the control and the β-blockade groups prior to β-blockade, LVFS and LVEF increased initially at week 2, consistent with an early compensatory hyperdynamic LV due to MR volume overload. However, LVESV was significantly higher and LVFS and LVEF were significantly lower in the β-blockade group than the control group at weeks 6, 12, and 24 after β-blocker treatment. Decreases in LVFS and LVEF were more pronounced in the β-blockade group than in the control group, although gradual decreases in LVFS and LVEF were also seen in the control group due to impairment of LV systolic function caused by chronic volume overload.
Effects of Late β-Blockade on LV Remodeling and Function

After echocardiography was performed at week 24 post MR induction, rats in the early control group were re-randomized into the late control group (n=20) and late β-blockade group (n=22). There were no significant differences in the heart rates, LV dimensions, volume, LVFS and LVEF between the late control and late β-blockade groups prior to late β-blocker treatment. However, heart rates were significantly lower, LV dimensions and volumes were larger and LVFS and LVEF were lower in the late-β-blockade group than the late control group (Table 4).

Effect of β-Blockade on Survival

Figure 2 presents the Kaplan-Meier survival curves in the control and β-blockade groups during the period of early β-blocker treatment. All rat deaths occurred 17 weeks post MR induction when LVEF and LVFS had significantly decreased with substantial LV remodeling in both the control and β-blockade groups. The survival probability was 96% (95% confidence interval: 90-100%) in the control group and 88% (95% confidence interval: 79-98%, p=0.03) in the β-blockade group. During the period of late β-blocker treatment, there were 1 death (n=19, 5%) in the β-blockade withdrawn group, 3 deaths (n=20, 15%) in the late control group, 5 deaths (n=22, 23%) in the late β-blockade group, and 6 deaths (n=19, 32%) in the long-term β-blockade group. Long-term and late β-blockade did not show to prolong survival.

Discussion

In humans with chronic organic MR, increases in LVESD and LVESV indicate adverse LV remodeling which is associated with a poor prognosis. These measures provide threshold values indicating a need for valve surgery. Since non-selective β-blockade is effective at preventing
and reversing adverse LV remodeling in patients with ischemic and dilated cardiomyopathies, it has been suggested that it might be of benefit in organic MR. Prior studies showed β-blockade improved LV function in canine models of chronic organic MR and in patients with degenerative mitral valve disease in pilot clinical studies. However, the effect of β-blockade on LV remodeling in chronic organic MR is uncertain and appears to be different from that on LV function. No prior studies have demonstrated beneficial effects of β-blockade on LV remodeling in organic MR. Therefore, the dissociation between a reported improvement in LV function (LVEF) and a lack of effect on LV remodeling in chronic organic MR treated with β-blockers requires further investigation.

**Beta-Blockade in Chronic Organic MR**

The sympathetic nervous system may be activated in experimental MR and in patients with chronic MR and LV dysfunction. Carabello and colleagues reported that β1-blockade restored impaired LV systolic function in a canine model of chronic organic MR with congestive heart failure. This beneficial effect on LV systolic function appeared to result from the bradycardia induced by β-blockade since it was not present when bradycardia was prevented by pacing. Effect of β1-selective-blockade on hemodynamics in chronic organic MR includes decreases in heart rate and blood pressure and increases in LV end-diastolic and LV end-systolic volumes. Increase in forward stroke volume was associated with a reduction in blood pressure.

This study, however, showed that non-selective β-blockade had no beneficial effect on LV remodeling in a rat model of chronic organic MR. In contrast, β-blockade appeared to accelerate the progression of LV remodeling and was associated with worsened LV function with long-term treatment. Although heart rates were significantly reduced in the β-blockade
groups there was no survival benefit. Our findings are consistent with a previous experimental study that β-blockade could cause significant increases in LV dimensions and volumes. Non-beneficial effect of β-blockade on LV remodeling was also observed in patients with organic MR and normal LV function. Furthermore, in a prior study of volume overload caused by aortocaval shunt, LV weight was significantly greater in rats treated with a β-blocker than those without β-blocker treatment. These findings suggest that the pathophysiology of LV remodeling caused by primary volume overload such as organic MR may be different from other forms of congestive heart failure in which myocardial damage (ischemic heart disease, cardiomyopathy) is the primary insult.

**Differences in β-Blockers**

In prior studies, β1-adrenergic receptor antagonists (atenolol and metoprolol) were used in the treatment of organic MR. In this study, carvedilol (a non-selective adrenergic receptor antagonist) was used since it has beneficial effects of reducing heart rate and afterload as well as improving myocardial contractility and LVEF in congestive heart failure. Similar to previous findings, heart rate and blood pressure decreased in the β-blockade group in the current study. Rats with organic MR tolerated carvedilol well at the early stages of MR. There were no deaths in the first 17-weeks after carvedilol treatment, which excludes the possibility of catastrophic deterioration of hemodynamics such as cardiogenic shock due to the combination of α1 and β1-receptor blockade. Recent literature shows that α1- receptors may have “protective effects” in congestive heart failure and blockade of α1- receptors could have deleterious effects. Whether the adverse effect of carvedilol on LV remodeling and function in chronic organic MR is related to the blockade of α1-adrenergic receptor and/or β2-receptor is unknown.
This is clinically relevant since several prior studies have called for clinical trials of β-blocker treatment in chronic organic MR.

**Future Studies**

The inability to demonstrate overall beneficial effect of neurohormonal antagonists (angiotensin converting enzyme inhibitor, angiotensin II receptor blocker and β-blocker) on LV remodeling in chronic organic MR suggests the pathophysiology of congestive heart failure caused by chronic organic MR may be different from non-organic MR due to ischemic heart disease or cardiomyopathy. A possible explanation for the detrimental effects of early β-blockade in chronic organic MR may be that β-blockade deprives LV systolic function and myocardial contractility, which is normally maintained by the sympathetic nervous system. Long-term depression of myocardial contractility could lead to failure to maintain a normal LV end-systolic dimension in the condition of significant volume overload imposed by severe MR. Dilation of LV end-systolic dimension increases LV wall stress and mechanical stretching of myocytes. This could activate the signaling pathways accelerating the loss of the myocardial extracellular matrix and downregulation of noncollagen extracellular matrix which could lead to LV dilation and adverse remodeling. In the long term, significant LV remodeling is associated with deterioration of LV function. The early study from Cooper’s group demonstrated that most of the deleterious effects of chronic organic MR appeared to be due to a combination of myofibrillar loss and failure of compensatory hypertrophy. The recent molecular study from Delli’Italia and colleagues confirmed that myocardial extracellular matrix loss and LV remodeling was more significant in canine models of organic MR treated with β-
blockers. Therefore, studies of interventions to prevent LV remodeling and reduce extracellular matrix loss may be important for managing this unique pathophysiology.

Limitations of the Study

Although rat models of cardiovascular disease have been successfully used to test multiple medical therapies a rat model of chronic organic MR is relatively new. In addition, mitral regurgitation is acutely and mechanically induced in all animal models of organic MR. Progression of LV remodeling, therefore may be different from patients with degenerative mitral valve disease in which the severity of MR often increases gradually unless rupture of the chordae tendineae of the mitral valve occurs. Although this study evaluated the effect of β-blockade in acute and chronic stages of organic MR by designating the early and late β-blockade groups one should not over-extrapolate experimental results to clinical patients. Adverse effects of non-selective β-blockade on LV remodeling, function and survival in the rat model of chronic MR warrants further investigation in large animal models or humans. The current experimental study provides additional information to investigators prior to the initiation of a clinical trial of β-blocker therapy for chronic organic MR.
Acknowledgments

The authors would like to thank William C. Little MD for reviewing and editing the original and revised manuscript and Timothy M. Morgan PhD for statistical analysis.

Sources of Funding

This study was in part supported by a grant from the Pennsylvania Tobacco Settlement Fund and the Penn State College of Medicine. Dr. Pu was in part supported by the Scientist Development Grant from the American Heart Association. Carvedilol was provided by GlaxoSmithKline.

Disclosures

None.

References


Table 1. Effect of Carvedilol on Heart Rate

<table>
<thead>
<tr>
<th>Heart Rate (b/min)</th>
<th>Baseline</th>
<th>Week 2</th>
<th>Week 6</th>
<th>Week 12</th>
<th>Week 24</th>
<th>Group main effect</th>
<th>Group by week interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>370 ± 37</td>
<td>388 ± 34</td>
<td>359 ± 48</td>
<td>352 ± 35</td>
<td>351 ± 31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-blockade</td>
<td>365 ± 37</td>
<td>379 ± 32</td>
<td>317 ± 29</td>
<td>315 ± 22</td>
<td>308 ± 25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P values</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
<td>0.68</td>
</tr>
</tbody>
</table>

There are no differences in heart rate between the control and β-blockade groups at baseline and week 2 (p values >0.05).
Table 2. Effect of Carvedilol on Blood Pressure

<table>
<thead>
<tr>
<th>Blood pressure</th>
<th>Control (n=13)</th>
<th>BB withdrawal (n=15)</th>
<th>Late BB (n=13)</th>
<th>Long-term BB (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic BP (mmHg)</td>
<td>114 ± 10</td>
<td>108 ± 13</td>
<td>101 ± 12 **</td>
<td>93 ± 12 **</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>84 ± 7</td>
<td>81 ± 10</td>
<td>73 ± 10 **</td>
<td>73 ± 9 *</td>
</tr>
</tbody>
</table>

Comparison between the control and long-term β-blockade withdrawn groups: *p<0.01, **p<0.005. There were no statistical differences in systolic and diastolic blood pressures between the control and β-blockade withdrawn groups. BB: β-blockade
Table 3. Effects of Early β-Blockade on LV Remodeling and Function

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 2</th>
<th>Week 6</th>
<th>Week 12</th>
<th>Week 24</th>
<th>Group main effect</th>
<th>Group by week interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LVEDV (ml)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.54 ± 0.13</td>
<td>0.76 ± 0.18</td>
<td>1.21 ± 0.34</td>
<td>1.40 ± 0.41</td>
<td>1.59 ± 0.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-blockade</td>
<td>0.55 ± 0.11</td>
<td>0.79 ± 0.19</td>
<td>1.54 ± 0.47</td>
<td>1.74 ± 0.50</td>
<td>2.20 ± 0.70</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LVESV (ml)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.12 ± 0.05</td>
<td>0.11 ± 0.05</td>
<td>0.28 ± 0.14</td>
<td>0.34 ± 0.16</td>
<td>0.40 ± 0.19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-blockade</td>
<td>0.12 ± 0.05</td>
<td>0.11 ± 0.06</td>
<td>0.45 ± 0.21</td>
<td>0.51 ± 0.21</td>
<td>0.72 ± 0.42</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>LV mass index (g/kg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>2.26 ± 0.26</td>
<td>2.69 ± 0.43</td>
<td>2.49 ± 0.52</td>
<td>2.46 ± 0.61</td>
<td>2.40 ± 0.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-blockade</td>
<td>0.26 ± 0.26</td>
<td>0.26 ± 0.38</td>
<td>0.26 ± 0.39</td>
<td>0.26 ± 0.39</td>
<td>0.26 ± 0.39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td>&lt;0.018</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LVFS (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>41 ± 8</td>
<td>49 ± 7</td>
<td>49 ± 7</td>
<td>49 ± 9</td>
<td>0.38 ± 0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-blockade</td>
<td>50 ± 7</td>
<td>50 ± 7</td>
<td>50 ± 7</td>
<td>50 ± 7</td>
<td>33 ± 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P values</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>LVEF (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>78 ± 7</td>
<td>86 ± 7</td>
<td>78 ± 7</td>
<td>78 ± 7</td>
<td>75 ± 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-blockade</td>
<td>78 ± 8</td>
<td>87 ± 8</td>
<td>71 ± 8</td>
<td>71 ± 7</td>
<td>69 ± 11</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>P values</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

There are no differences in LVEDV, LVESV, LV mass index, LVFS and LVEF between the control and β-blockade groups at baseline and week 2 (all p values >0.05).
Table 4. Effect of Late β-Blockade on LV Remodeling and Function

<table>
<thead>
<tr>
<th></th>
<th>Week 24</th>
<th>Week 24</th>
<th>Week 36</th>
<th>Week 36</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Late control (n=20)</td>
<td>Late BB (n=22)</td>
<td>Late control (n=16)</td>
<td>Late BB (n=17)</td>
</tr>
<tr>
<td>LVEDD (cm)</td>
<td>1.13±0.12</td>
<td>1.14±0.14</td>
<td>1.15±0.13</td>
<td>1.23±0.14</td>
</tr>
<tr>
<td>LVESD (cm)</td>
<td>0.69±0.10</td>
<td>0.73±0.13</td>
<td>0.73±0.14</td>
<td>0.85±0.19*</td>
</tr>
<tr>
<td>LVEDV (ml)</td>
<td>1.55±0.53</td>
<td>1.63±0.61</td>
<td>1.66±0.57</td>
<td>2.02±0.83</td>
</tr>
<tr>
<td>LVESV (ml)</td>
<td>0.36±0.15</td>
<td>0.43±0.23</td>
<td>0.45±0.25</td>
<td>0.73±0.51*</td>
</tr>
<tr>
<td>LVFS (%)</td>
<td>39±7</td>
<td>37±6</td>
<td>37±7</td>
<td>31±7*</td>
</tr>
<tr>
<td>LVEF</td>
<td>76±7</td>
<td>74±7</td>
<td>74±7</td>
<td>66±11*</td>
</tr>
<tr>
<td>Heart rate (b/min)</td>
<td>352±24</td>
<td>351±37</td>
<td>341±29</td>
<td>307±43**</td>
</tr>
</tbody>
</table>

Comparison between the late control group and the late β-blockade group: * p<0.05; ** p<0.001
Figure Legends

Figure 1. Study protocol with early and late β-blockade. (BB: beta-blockade)

Figure 2. Cumulative survival in the β-blockade and the MR control group are presented in Kaplan-Meier analysis. All rat deaths occurred after 17 weeks post MR induction when adverse LV remodeling and impaired LV function were significant in both the β-blockade and control group. Estimated survival probability was lower in the early β-blockade group than the control group.
Effects of Early, Late and Long-term Non-Selective Beta-Blockade on Left Ventricular Remodeling, Function and Survival in Chronic Organic Mitral Regurgitation

Min Pu, Zhaohui Gao, Daniel K. Pu and William R. Davidson, Jr.

Circ Heart Fail. published online April 11, 2013;
Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/early/2013/04/11/CIRCHEARTFAILURE.112.000196

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Heart Failure can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Heart Failure is online at:
http://circheartfailure.ahajournals.org/subscriptions/